BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
5 Must-Attempt Fascinating Dishes from Around the World - 2Nature's Treats: 10 Organic products That Lift Prosperity
- 36 Popular Men's Aromas On the planet
- 4Figure out how to Perceive Warnings while Looking for an Auto Collision Lawyer
- 5Find the Keys to Fruitful Venture The board: Conveying Results on Time
- Experience Unrivaled Sound: Top Speakers You Really want to Hear
- A few Up-to-date Sacks - Stylish Young ladies Shouldn't Miss
- Fundamental Home Exercise center Hardware: Amplify Your Exercises
- Ancient eggshells shed new light on crocodiles that hunted prey from trees
- Uzbekistan launches €9.46 billion green energy push, covering nation’s power needs
- 4 Family SUVs: Joining Solace and Style
- 'The Beast in Me' arrives on Netflix: Is it based on a true story? And what drew Claire Danes to it? What to know about the thriller series.
- Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- Immortal Style: Closet Staples for Each Age
